Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Unity Biotechnology Is Getting Crushed Today

By Maxx Chatsko – Aug 17, 2020 at 12:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The development-stage biopharma announced disappointing results from a clinical trial.

What happened

Shares of Unity Biotechnology (UBX -3.54%) fell over 63% today after the company announced disappointing results from a clinical trial involving its lead drug candidate, UBX0101. 

At the 12-week mark of a phase 2 study, the pipeline asset failed to meet its primary endpoint in alleviating moderate to severe painful osteoarthritis (OA) of the knee. In fact, there were no statistically significant differences between any dose of UBX0101 and placebo.

As of 1:22 p.m. EDT, the small-cap stock had settled to a 61.3% loss.

A shocked woman checking her phone.

Image source: Getty Images.

So what

Unity Biotechnology is developing a drug pipeline based on the idea that clearing senescent cells, or cells that stop dividing, can help to treat or reverse age-related diseases. The idea has been around for decades and has begun to gain traction in recent years with new developments in living technologies.

Of course, many cellular mechanisms and biomolecules often have multiple roles in the body. Proteins that trigger processes to reduce inflammation in some settings can trigger processes that increase inflammation in other settings. Similarly, senescent cells aren't always a sign of age-related diseases. They play important roles from the development of embryos to the health of centenarians. 

It's possible that a mechanism to finely control senescent cell populations related to age-related diseases -- while sparing health-related cell populations -- will be discovered and commercialized, but there are simply too many unknowns for investors to confidently bet on any pipeline or technology. 

Now what

Unity Biotechnology reported it will complete data collection through the 24-week mark of the phase 2 trial, although it doesn't intend to advance UBX0101 in phase 3 trials. Its next-most advanced pipeline asset is UBX1325, which has yet to enter clinical trials. Given the lack of data to support the pipeline, Unity's $250 million market valuation seems about right, if not generous.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Unity Biotechnology, Inc. Stock Quote
Unity Biotechnology, Inc.
$0.40 (-3.54%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.